Which of the following is true regarding the initiation of Mellitofix in patients hospitalized with acute heart failure?, It is safe to initiate early (within 2–5 days of admission) once the patient is hemodynamically stable., It requires intensive dose-titration starting at 2.5 mg and moving up to 25 mg over several weeks., It must be strictly avoided until at least 30 days post-discharge to prevent severe kidney injury., It should only be initiated if the patient has comorbid type 2 diabetes., Mellitofix should not be used in patients with:, HFrEF without T2D., Type 1 diabetes mellitus, Elderly patients (Over 65 years old), eGFR <45 mL/min/1.73m2., The Standard recommended dose for Mellitofix in HF and CKD patients is:, 5 mg once daily, 10 mg once daily, 25 mg once daily, 5 mg twice daily, What is the ESC class and level of evidence for the use of Mellitofix and Dapagliflozin-Eva Pharma in HFrEF patients?, Class I, Level B, Class IIa, Level A, Class I, Level A, Class IIb, Level B, What is the primary advantage of Marvitense single-pill triple therapy over free combinations?, Lower cost , Improved therapeutic adherence and persistence , Faster onset of action, delayed onset of action, Which patient criteria warrant dose reduction to 2.5 mg BID for Apixatrack ?, Age ≥65 years , Weight <60 kg , Age ≥80 years, weight ≤60 kg, and serum creatinine ≥1.5 mg/dL (need ≥2 of 3) , Any degree of renal impairment , Mild hepatic impairment.
0%
Quiz 2
Share
Share
Share
by
Eyeegypt
Edit Content
Print
Embed
More
Assignments
Leaderboard
Show more
Show less
This leaderboard is currently private. Click
Share
to make it public.
This leaderboard has been disabled by the resource owner.
This leaderboard is disabled as your options are different to the resource owner.
Revert Options
Quiz
is an open-ended template. It does not generate scores for a leaderboard.
Log in required
Visual style
Fonts
Subscription required
Options
Switch template
Show all
More formats will appear as you play the activity.
Open results
Copy link
QR code
Delete
Continue editing:
?